Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -238.11 Million CNY | -175.84% |
| 2022 | 1.13 Billion CNY | 46.81% |
| 2021 | 773.2 Million CNY | -41.86% |
| 2020 | 1.32 Billion CNY | 1.16% |
| 2019 | 1.31 Billion CNY | 82.31% |
| 2018 | 721.14 Million CNY | 9843.16% |
| 2017 | -7.4 Million CNY | -101.7% |
| 2016 | 435.61 Million CNY | -32.35% |
| 2015 | 643.89 Million CNY | 65.02% |
| 2014 | 390.18 Million CNY | 3.98% |
| 2013 | 375.25 Million CNY | -48.38% |
| 2012 | 727 Million CNY | 1.03% |
| 2011 | 719.57 Million CNY | -49.21% |
| 2010 | 1.41 Billion CNY | 47.6% |
| 2009 | 959.76 Million CNY | 384.99% |
| 2008 | 197.89 Million CNY | 170.38% |
| 2007 | 73.19 Million CNY | 40.91% |
| 2006 | 51.94 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 196.84 Million CNY | 118.93% |
| 2024 Q2 | 586.49 Million CNY | 197.94% |
| 2023 Q3 | 14.86 Million CNY | -83.53% |
| 2023 Q2 | 90.3 Million CNY | 22.61% |
| 2023 Q4 | -1.03 Billion CNY | -7092.78% |
| 2023 Q1 | 73.64 Million CNY | 654.12% |
| 2023 FY | -860.91 Million CNY | -175.84% |
| 2022 Q2 | 346.45 Million CNY | 22.21% |
| 2022 Q4 | -13.29 Million CNY | -106.27% |
| 2022 FY | 1.13 Billion CNY | 46.81% |
| 2022 Q1 | 283.49 Million CNY | 185.25% |
| 2022 Q3 | 211.96 Million CNY | -38.82% |
| 2021 FY | 773.2 Million CNY | -41.86% |
| 2021 Q1 | 182.25 Million CNY | -62.17% |
| 2021 Q2 | 236.91 Million CNY | 29.99% |
| 2021 Q3 | 140.85 Million CNY | -40.55% |
| 2021 Q4 | -332.55 Million CNY | -336.1% |
| 2020 Q3 | 154.74 Million CNY | -60.17% |
| 2020 Q2 | 388.5 Million CNY | 27.4% |
| 2020 Q1 | 304.95 Million CNY | -43.58% |
| 2020 FY | 1.32 Billion CNY | 1.16% |
| 2020 Q4 | 481.75 Million CNY | 211.31% |
| 2019 Q1 | 580.55 Million CNY | 204.7% |
| 2019 Q2 | 43.69 Million CNY | -92.47% |
| 2019 Q3 | 150.01 Million CNY | 243.3% |
| 2019 Q4 | 540.46 Million CNY | 260.27% |
| 2019 FY | 1.31 Billion CNY | 82.31% |
| 2018 Q1 | 48.53 Million CNY | 212.2% |
| 2018 FY | 721.14 Million CNY | 9843.16% |
| 2018 Q2 | 202.4 Million CNY | 317.05% |
| 2018 Q3 | 244.19 Million CNY | 20.65% |
| 2018 Q4 | 190.53 Million CNY | -21.98% |
| 2017 Q4 | -43.25 Million CNY | -197.78% |
| 2017 Q1 | -24.68 Million CNY | -125.24% |
| 2017 FY | -7.4 Million CNY | -101.7% |
| 2017 Q2 | 16.3 Million CNY | 166.05% |
| 2017 Q3 | 44.23 Million CNY | 171.29% |
| 2016 Q4 | 97.8 Million CNY | 148.27% |
| 2016 Q2 | 73.62 Million CNY | -67.25% |
| 2016 Q1 | 224.78 Million CNY | 43.05% |
| 2016 FY | 435.61 Million CNY | -32.35% |
| 2016 Q3 | 39.39 Million CNY | -46.49% |
| 2015 Q4 | 157.14 Million CNY | 3.27% |
| 2015 FY | 643.89 Million CNY | 65.02% |
| 2015 Q3 | 152.17 Million CNY | 48.39% |
| 2015 Q2 | 102.55 Million CNY | -55.8% |
| 2015 Q1 | 232.02 Million CNY | 117.71% |
| 2014 Q3 | 136.59 Million CNY | 125.69% |
| 2014 Q1 | 86.48 Million CNY | 208.1% |
| 2014 Q4 | 106.57 Million CNY | -21.97% |
| 2014 FY | 390.18 Million CNY | 3.98% |
| 2014 Q2 | 60.52 Million CNY | -30.02% |
| 2013 Q4 | 28.07 Million CNY | -46.47% |
| 2013 FY | 375.25 Million CNY | -48.38% |
| 2013 Q1 | 166.96 Million CNY | 0.14% |
| 2013 Q2 | 127.78 Million CNY | -23.47% |
| 2013 Q3 | 52.43 Million CNY | -58.96% |
| 2012 Q3 | 177.49 Million CNY | -0.26% |
| 2012 Q2 | 177.95 Million CNY | -13.12% |
| 2012 FY | 727 Million CNY | 1.03% |
| 2012 Q1 | 204.83 Million CNY | 54.22% |
| 2012 Q4 | 166.73 Million CNY | -6.06% |
| 2011 Q3 | 169.74 Million CNY | -28.78% |
| 2011 Q1 | 178.66 Million CNY | -41.41% |
| 2011 FY | 719.57 Million CNY | -49.21% |
| 2011 Q4 | 132.81 Million CNY | -21.76% |
| 2011 Q2 | 238.34 Million CNY | 33.41% |
| 2010 Q1 | 293.61 Million CNY | -29.64% |
| 2010 FY | 1.41 Billion CNY | 47.6% |
| 2010 Q4 | 304.94 Million CNY | -26.24% |
| 2010 Q3 | 413.45 Million CNY | 2.18% |
| 2010 Q2 | 404.61 Million CNY | 37.8% |
| 2009 FY | 959.76 Million CNY | 384.99% |
| 2009 Q1 | 155.03 Million CNY | 0.0% |
| 2009 Q3 | 216.31 Million CNY | 26.41% |
| 2009 Q4 | 417.29 Million CNY | 92.91% |
| 2009 Q2 | 171.12 Million CNY | 10.38% |
| 2008 FY | 197.89 Million CNY | 170.38% |
| 2007 FY | 73.19 Million CNY | 40.91% |
| 2006 FY | 51.94 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 266.498% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 108.94% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | -2817.325% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 682.466% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | -356.302% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 760.652% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 176.729% |
| Tongfang Kontafarma Holdings Limited | - HKD | Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | -260.525% |
| SSY Group Limited | 1.63 Billion HKD | 114.529% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 236.685% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 171.478% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 101.96% |